Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens

被引:1
|
作者
Hao, Qing [1 ]
Long, Yuhang [1 ]
Yang, Yi [1 ]
Deng, Yiqi [1 ,2 ]
Ding, Zhenyu [1 ]
Yang, Li [1 ]
Shu, Yang [1 ,3 ,4 ]
Xu, Heng [1 ,4 ,5 ]
机构
[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Dept Biotherapy, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Hosp, Gastr Canc Ctr, Dept Gen Surg, Chengdu 610041, Peoples R China
[4] Sichuan Univ, West China Hosp, Inst Gen Surg, Chengdu 610041, Peoples R China
[5] Sichuan Univ, West China Hosp, Res Ctr Clin Lab Med, Dept Lab Med, Chengdu 610041, Peoples R China
基金
国家重点研发计划;
关键词
neoantigen; therapeutic cancer vaccines; cancer immunotherapy; PEPTIDE BINDING; LUNG-CANCER; CELL; PREDICTION; IMMUNOTHERAPY; BLOCKADE; IDENTIFICATION; MUTATIONS; IMMUNITY; TRIAL;
D O I
10.3390/vaccines12070717
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neoantigens, presented as peptides on the surfaces of cancer cells, have recently been proposed as optimal targets for immunotherapy in clinical practice. The promising outcomes of neoantigen-based cancer vaccines have inspired enthusiasm for their broader clinical applications. However, the individualized tumor-specific antigens (TSA) entail considerable costs and time due to the variable immunogenicity and response rates of these neoantigens-based vaccines, influenced by factors such as neoantigen response, vaccine types, and combination therapy. Given the crucial role of neoantigen efficacy, a number of bioinformatics algorithms and pipelines have been developed to improve the accuracy rate of prediction through considering a series of factors involving in HLA-peptide-TCR complex formation, including peptide presentation, HLA-peptide affinity, and TCR recognition. On the other hand, shared neoantigens, originating from driver mutations at hot mutation spots (e.g., KRASG12D), offer a promising and ideal target for the development of therapeutic cancer vaccines. A series of clinical practices have established the efficacy of these vaccines in patients with distinct HLA haplotypes. Moreover, increasing evidence demonstrated that a combination of tumor associated antigens (TAAs) and neoantigens can also improve the prognosis, thus expand the repertoire of shared neoantigens for cancer vaccines. In this review, we provide an overview of the complex process involved in identifying personalized neoantigens, their clinical applications, advances in vaccine technology, and explore the therapeutic potential of shared neoantigen strategies.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] Identification of neoantigens for individualized therapeutic cancer vaccines
    Franziska Lang
    Barbara Schrörs
    Martin Löwer
    Özlem Türeci
    Ugur Sahin
    Nature Reviews Drug Discovery, 2022, 21 : 261 - 282
  • [2] Identification of neoantigens for individualized therapeutic cancer vaccines
    Lang, Franziska
    Schroers, Barbara
    Loewer, Martin
    Tuereci, Oezlem
    Sahin, Ugur
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 261 - 282
  • [3] Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines
    Franziska Lang
    Barbara Schrörs
    Martin Löwer
    Özlem Türeci
    Ugur Sahin
    Nature Reviews Drug Discovery, 2024, 23 : 156 - 156
  • [4] Identification of neoantigens for individualized therapeutic cancer vaccines (vol 21, pg 261, 2022)
    Lang, Franziska
    Schroers, Barbara
    Loewer, Martin
    Tuereci, Oezlem
    Sahin, Ugur
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (02) : 156 - 156
  • [5] The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines
    Chakraborty, Chiranjib
    Majumder, Anirban
    Bhattacharya, Manojit
    Chatterjee, Srijan
    Lee, Sang -Soo
    CURRENT RESEARCH IN BIOTECHNOLOGY, 2024, 7
  • [6] Design of clinical trials for therapeutic cancer vaccines development
    Mackiewicz, Jacek
    Mackiewicz, Andrzej
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) : 84 - 89
  • [7] Development of neoantigens: from identification in cancer cells to application in cancer vaccines
    Ebrahimi, Nasim
    Akbari, Maryam
    Ghanaatian, Masoud
    Moghaddam, Parichehr Roozbahani
    Adelian, Samaneh
    Boroujeni, Marziyeh Borjian
    Yazdani, Elnaz
    Ahmadi, Amirhossein
    Hamblin, Michael R.
    EXPERT REVIEW OF VACCINES, 2022, 21 (07) : 941 - 955
  • [8] Clinical trial designs for the early clinical development of therapeutic cancer vaccines
    Simon, RM
    Steinberg, SM
    Hamilton, M
    Hildesheim, A
    Khleif, S
    Kwak, LW
    Mackall, CL
    Schlom, J
    Topalian, SL
    Berzofsky, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1848 - 1854
  • [9] Therapeutic bispecific antibody targeting shared neoantigens
    Wu, Xiaojing
    Nakamura, Yusuke
    Kiyotani, Kazuma
    CANCER SCIENCE, 2024, 115 : 2069 - 2069
  • [10] Clinical development of MVA-based therapeutic cancer vaccines
    Acres, Bruce
    Bonnefoy, Jean-Yves
    EXPERT REVIEW OF VACCINES, 2008, 7 (07) : 889 - 893